Hematology ·
Upfront genome and transcriptome sequencing diagnoses 36.7% of suspected IBMFS cases
In a cohort of 237 patients with suspected inherited bone marrow failure syndromes (IBMFS), upfront whole-genome and transcriptome sequencing (WGTS) produced a molecular diagnosis in 87 patients (36.7%). The study also identified other genetic diagnoses and actionable findings, supporting further evaluation of WGTS in this diagnostically challenging population.
- WGTS diagnosed IBMFS in 87 of 237 patients.
- The cohort included children and adults with suspected IBMFS.
- Four other genetic diagnoses and seven actionable findings were reported.
- Comparative performance and implementation details are not provided.
Inherited bone marrow failure syndromes can be difficult to distinguish from one another and from acquired conditions such as immune aplastic anemia. This study evaluated clinically accredited, upfront whole-genome and transcriptome sequencing using non-hematopoietic DNA in 237 patients with suspected IBMFS. Median age was 29 years (range, 3 months to 76 years); 34.6% were younger than 18. Results were returned in real time to inform management and familial testing.
A molecular diagnosis of IBMFS was established in 87 patients (36.7%), across conditions including hereditary thrombocytopenia, telomere biology disorders, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome and Fanconi anemia. Sequencing also identified four non-hematological genetic conditions and seven secondary actionable findings. The authors report novel disease mechanisms and gene-disease associations; acceptability among patients and carers was high.
These findings suggest WGTS may help resolve suspected IBMFS cases and identify findings relevant to patients and families. The abstract does not provide a comparison group or detail diagnostic performance by syndrome, and the results do not establish that this approach should replace existing testing pathways. The evidence comes from a single reported cohort; full-text methods and limitations were not available in the supplied source.
In practice
For children and adults with suspected inherited bone marrow failure syndromes, upfront whole-genome and transcriptome sequencing using non-hematopoietic DNA yielded a molecular diagnosis in 36.7% of this 237-patient cohort, with additional genetic diagnoses and secondary actionable findings reported. The results support the potential diagnostic value of WGTS in this setting, but do not establish superiority over existing pathways or justify replacing targeted testing. The supplied abstract lacks a comparator and detailed syndrome-specific performance data; practice implications therefore remain uncertain.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood: Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.